Biologic therapy is not associated with increased COVID-19 severity in patients with hidradenitis suppurativa: Initial findings from the Global Hidradenitis Suppurativa COVID-19 Registry

Haley B. Naik, Raed Alhusayen, John Frew, Sandra Guilbault, Nancy K. Hills, John R. Ingram, Margaret V. Kudlinski, Michelle A. Lowes, Angelo Valerio Marzano, Maia Paul, Bente Villumsen, Christine A. Yannuzzi

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)249-252
JournalJournal of the American Academy of Dermatology
Volume86
Issue number1
DOIs
Publication statusPublished - 2022

Keywords

  • biologics
  • comorbidities
  • COVID
  • COVID-19
  • hidradenitis suppurativa
  • pandemic

ASJC Scopus subject areas

  • Dermatology

Cite this